565 related articles for article (PubMed ID: 27586020)
1. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
2. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human efflux transporter ABCC2 (MRP2) by self-emulsifying drug delivery system: influences of concentration and combination of excipients.
Li L; Yi T; Lam CW
J Pharm Pharm Sci; 2014; 17(4):447-60. PubMed ID: 25579428
[TBL] [Abstract][Full Text] [Related]
4. Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.
Järvinen E; Troberg J; Kidron H; Finel M
Mol Pharm; 2017 Oct; 14(10):3299-3311. PubMed ID: 28850245
[TBL] [Abstract][Full Text] [Related]
5. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
[TBL] [Abstract][Full Text] [Related]
6. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
7. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S
Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806
[TBL] [Abstract][Full Text] [Related]
9. Mrp2-related efflux of scutellarin in the intestinal absorption in rats.
Cao F; Zhang H; Guo J; Ping Q
Pharmazie; 2008 Jan; 63(1):75-80. PubMed ID: 18271309
[TBL] [Abstract][Full Text] [Related]
10. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
[TBL] [Abstract][Full Text] [Related]
12. Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells.
Brand W; Oosterhuis B; Krajcsi P; Barron D; Dionisi F; van Bladeren PJ; Rietjens IM; Williamson G
Biopharm Drug Dispos; 2011 Dec; 32(9):530-5. PubMed ID: 22083890
[TBL] [Abstract][Full Text] [Related]
13. Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.
Ge S; Yin T; Xu B; Gao S; Hu M
Pharm Res; 2016 Mar; 33(3):590-602. PubMed ID: 26502886
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
15. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
17. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.
Gedeon C; Behravan J; Koren G; Piquette-Miller M
Placenta; 2006; 27(11-12):1096-102. PubMed ID: 16460798
[TBL] [Abstract][Full Text] [Related]
18. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.
Lagas JS; van der Kruijssen CM; van de Wetering K; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Jan; 37(1):129-36. PubMed ID: 18845662
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
20. [Absorption and transportation characteristics of scutellarin and scutellarein across Caco-2 monolayer model].
You HS; Zhang HF; Dong YL; Chen SY; Wang MY; Dong WH; Xing JF
Zhong Xi Yi Jie He Xue Bao; 2010 Sep; 8(9):863-9. PubMed ID: 20836977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
